Thermo Fisher To Invest $180 M To Expand Viral Vector Mfg Capacity
Thermo Fisher Scientific is expanding capacity for viral vector development and manufacturing services with the construction of a new commercial manufacturing site in Plainville, Massachusetts. The $180-million project will more than double the company’s commercial viral vector capacity to support demand for the development and manufacture of gene therapies and vaccines.
Construction of the new 290,000-square-foot facility is expected to be completed in 2022. The project will add more than 200 jobs and complements recently expanded capacity at its sites in Lexington and Cambridge, Massachusetts and Alachua, Florida.
The Plainville site will offer a scalable configuration of laboratory and production suites co-located with adjacent warehousing and office space. An onsite engineering laboratory will provide develop turnkey production platforms to enable transition to commercial-scale operations.
Source: Thermo Fisher Scientific